Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
05-Jan-2026 | 319.75 | 321.5 | 315.05 | 317 | 10,448 | 5,99,70,921.4 | 1,09,144 |
06-Jan-2026 | 317 | 319.5 | 313.55 | 318.3 | 8,132 | 3,72,40,839.35 | 56,495 |
07-Jan-2026 | 319.95 | 320.15 | 315 | 318.15 | 7,057 | 3,70,21,195.15 | 61,022 |
08-Jan-2026 | 318.2 | 321.15 | 301.35 | 305.7 | 12,783 | 6,00,18,399.85 | 92,573 |
09-Jan-2026 | 305.7 | 307.1 | 296.85 | 301.65 | 18,462 | 13,77,10,742.25 | 2,55,656 |
12-Jan-2026 | 297 | 302.2 | 292.25 | 297.65 | 9,904 | 5,23,39,739.8 | 1,02,876 |
13-Jan-2026 | 297.9 | 299.4 | 292.6 | 294.9 | 8,904 | 3,66,51,303.95 | 66,154 |
14-Jan-2026 | 294.1 | 296.8 | 291.35 | 294.15 | 12,928 | 3,91,89,869.25 | 70,311 |
16-Jan-2026 | 294.45 | 296.85 | 288.1 | 291.8 | 12,520 | 7,00,89,451.7 | 1,35,701 |
19-Jan-2026 | 291.05 | 291.85 | 286.5 | 289.85 | 8,276 | 3,93,57,481.35 | 61,442 |
20-Jan-2026 | 290 | 290.5 | 277.1 | 279.2 | 11,280 | 5,86,73,968.9 | 1,20,493 |
21-Jan-2026 | 275 | 281.3 | 268.5 | 272.15 | 20,763 | 13,79,76,516.45 | 2,59,488 |
22-Jan-2026 | 270.15 | 283.2 | 268.1 | 270.1 | 15,468 | 10,03,45,210.05 | 2,23,625 |
23-Jan-2026 | 274.45 | 274.45 | 261.15 | 267 | 12,317 | 6,44,77,644.75 | 1,47,218 |
27-Jan-2026 | 270.05 | 270.2 | 259.5 | 268.35 | 13,706 | 5,98,76,848 | 1,04,976 |
28-Jan-2026 | 268 | 284.5 | 267.5 | 273.7 | 28,221 | 17,24,36,387.55 | 1,44,421 |
29-Jan-2026 | 275.85 | 275.9 | 268.35 | 269.95 | 9,529 | 4,50,36,231.6 | 81,285 |
30-Jan-2026 | 267.8 | 295 | 263.1 | 288.95 | 17,499 | 19,50,26,767.35 | 4,78,975 |
01-Feb-2026 | 294.75 | 325.3 | 275.5 | 288.1 | 1,28,632 | 1,66,67,70,577.6 | 3,62,044 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
